

## RESEARCH

# Study results – Cannabis Treatment for Seizure Activity with Lennox Gastaut Syndrome Patients

Study Performed by **DR. SAÚL GARZA MORALES**

**Institute(s):** 1. National Institute of Perinatology, Mexico City, Neuroscience 2. Hospital Espanol, Unidad de Neurodesarrollo, PEDIATRIA, Mexico City, Mexico 3. Instituto Mexicano del Seguro Social, Hosp. General regional 251, Toluca, Mexico

## INTRODUCTION

Lennox Gastaut Syndrome (LGS) remains as one of the most severe childhood encephalopathies with high seizure frequency (sudden falls, myoclonic and tonic), progressive cognitive impairment and antiepileptic drugs (AED) resistance.

**Method.** Between January 2016 and February 2017 45 patients with Lennox-Gastaut Syndrome (According to the criteria of the ILAE) with persistence of various seizures per day despite taking at least three anti-epileptic drugs were studied. Six patients were excluded from the study (one having started with a THC-containing compound and five who decided not to start the treatment).

## RESULTS

The remaining 39 cases took cannabidiol 100% pure (RSHO-X 5000 MG) in progressive doses of up to 5-7 mg/kg for at least 6 months of follow-up. All patients had imaging studies (CT or MRI) and at least two EEG studies. 50% presented hypoxic-ischemic encephalopathy or cortical malformations. All patients continued to take basal AED (3.7 per patient). The age was of  $10.9 \pm 6$  years (24/39 patients are male). All patients had various types of seizures (3.5/patient), dominating the atonic (74%) and focal (87%). 4 patients were callotomized for refractory epilepsy.

A significant reduction in the frequency of seizures (50%) was obtained in 84% of the cases (33/39) and 53% of the cases achieved an overall reduction of over 75% (21/39). A complete control of the events for at least 4 months was achieved in 7 cases (17%), an outstanding result for this type of patient. The seizures that achieved better results were atonic, absent and generalized tonic (30-100%), while focal seizures responded less to treatment (0-70%). Other benefits were observed in 89% of patients: alertness (43%), social interaction (40%), attention (30%), etc.

## CONCLUSION

Addition treatment with 100% Cannabidiol is a good alternative for patients with LGS and reduces the use and potential effects of tetrahydrocannabinol (THC).


## QUICK FACTS

Cannabis Product:  
**RSHO-X 5000mg**

### Lennox Gastaut Syndrome (LGS) POPULATION STATS

United States: **30,000**

World Wide: **300,000**



Source: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/#affected-populations>

## STUDY RESULTS

### DOSING:

**5-7mg CBD/kg body weight**

### MEDIAN SEIZURE REDUCTION REPORTED:

- » **84% reduction in motor seizures**
- » **53% report better than a 75% reduction in seizures**
- » **17% Report a Full or 100% Elimination of ALL Seizures Over a 4 Month Period**

### QUALITY OF LIFE IMPROVEMENTS:

- » **43% improvement in Alertness**
- » **40% improvement in Social Interaction**
- » **30% improvement in Attention**

### SIDE EFFECTS, ADVERSE:

**None reported**

## COMPARATIVE RESULTS

DR. SAÚL GARZA MORALES

Real Scientific Hemp Oil  
Lennox Gastaut Syndrome (LGS)

## DOSING

- » 5-7mg CBD/kg body weight  
Not taken every day

MEDIAN SEIZURE  
REDUCTION REPORTED

- » 84% reduction in motor seizures
- » Note that 53% report better than a 75% reduction in seizures
- » 17% elimination of ALL seizures over a 4 month period

QUALITY OF LIFE  
IMPROVEMENTS

- » 43% improvement in Alertness
- » 40% improvement in Social Interaction
- » 30% improvement in Attention

## SIDE EFFECTS, ADVERSE

- » None reported

## CONCLUSION

- » Treatment with cannabidiol is a good alternative for patients with LGS

DR. DEVINSKY EPIDIOLEX

Pharmaceutical Grade CBD  
Formal Pharma Study 2015

## DOSING

- » 25 - 50mg CBD/kg body weight  
Taken daily

MEDIAN SEIZURE  
REDUCTION REPORTED:

- » 36.5% reduction in motor seizures
- » No reports of over 50% seizure reduction

QUALITY OF LIFE  
IMPROVEMENTS

- » None reported
- » None reported
- » None reported

## SIDE EFFECTS, ADVERSE

- » 30% experienced Serious Adverse Events including one death

## SIDE EFFECTS, MODEST

- » None reported